Genix Pharmaceuticals EBIT

Genix Pharmaceuticals (GENPF) currently reports a EBIT of $-120K as of April 2026. That compares with $63K in the prior-year period — down 284.2% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Genix Pharmaceuticals's EBIT history and peer comparisons.

Genix Pharmaceuticals's EBIT decreased from $63K to $-120K — a 284.2% year-over-year decrease (period ending April 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Genix Pharmaceuticals's EBIT of $-120K is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Genix Pharmaceuticals reported $-120K in EBIT as of April 2026. That compares with $63K in the prior-year period — down 284.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-120K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Genix Pharmaceuticals, and consider following GENPF for alerts when major investors trade the stock.